Enable Accessibility Enable Accessibility

Director/PDMR Shareholding

April 1, 2010

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”) announces that it was notified on March 31, 2010 that on the same day the following Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) in the Company had been allocated under the Executive Annual Incentive Plan (the “Plan”) to the Executive Directors and Persons Discharging Managerial Responsibility (“PDMRs”) set out below. The Shares and ADSs were bought on the market on March 31, 2010 at prices of £14.54 per Share and US$66.0571 per ADS.  The allocations are in respect of performance in 2009.

 

Name of Director

Type of Security

Number of Shares/ADSs purchased

 

Angus Russell

ADSs 

7,421

 

Graham Hetherington

Shares

12,569

 
       

Name of PDMR

Type of Security

Number of Shares/ADSs purchased

 

Michael Cola

ADSs

3,375

 

Barbara Deptula

ADSs

2,463

 

Anita Graham

ADSs

2,085

 

Sylvie Gregoire

ADSs

3,506

 

 Tatjana May

Shares

7,515

 

Under the terms of the Plan, the Shares and ADSs will not normally be released to participants for three years.  One ADS is equal to three Shares.

In addition, on March 31, 2010 the Company was notified of the release of Shares and ADSs in the Company on March 30, 2010 in connection with awards made in 2007 under the Plan to persons who were, at the time of the award, Executive Directors and PDMRs.

In accordance with the rules of the Plan, the following Shares/ADSs were released:

 

Name of Director

Type of Security

Number of Shares/ADSs purchased

Number of Shares/ADSs sold to satisfy liabilities

Matthew Emmens

ADSs 

11,534

5,049

Angus Russell

Shares

18,140

7,574

       

Name of PDMR

Type of Security

Number of Shares/ADSs purchased

Number of Shares/ADSs sold to satisfy liabilities

Michael Cola

ADSs

2,944

1,132

Barbara Deptula

ADSs

2,402

1,019

Anita Graham

ADSs

2,072

797

Tatjana May

Shares

8,952

3,737

All Directors and PDMRs sold sufficient Shares or ADSs, on March 30, 2010, at prices of £14.60 per Share and $66.0098 per ADS to satisfy tax liabilities as set out above. 

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 781 482 0999

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.